Garg Pushkal

Garg Pushkal, Executive Vice President and Chief R&D Officer at Alnylam Pharmaceuticals (ALNY), has demonstrated a consistent pattern of selling company stock over time, with no recorded purchases in SEC filings. According to Form 4 disclosures, Pushkal has executed 90 transactions exclusively involving ALNY shares, all of which were sales, totaling approximately $9.39 million in aggregate value. The most recent activity, concentrated in early March 2026, includes 24 separate sales between March 2 and March 5, with individual transactions ranging from $13,970 to $248,385. Notably, the largest single sale occurred on March 4, when Pushkal disposed of shares worth $248,385.28, followed by multiple mid-sized transactions exceeding $100,000 each on subsequent days. The transactions reveal a clear directional bias toward divestment, with no offsetting purchases in either historical or recent filings. Pushkal’s sales are methodical, often executed in clusters across consecutive trading days—such as the eight separate sales on March 4 totaling over $800,000 combined. While the filings do not specify whether the sales were prearranged (e.g., 10b5-1 plans), the pattern aligns with an ongoing reduction in exposure to ALNY equity. The absence of buying activity, coupled with the frequency and scale of disposals, suggests a sustained effort to monetize holdings rather than accumulate additional shares. All transactions pertain solely to Alnylam, indicating no diversification into other equities via insider filings.